Ruitouch Technology Secures Nearly RMB 100 Million Series A Funding to Advance Multi-Pipeline Surgical Robot Development

Recently, Shanghai Simpletouch Technology Co., Ltd. (hereinafter referred to as “Simpletouch”), a surgical robotics company, announced the completion of its Series A financing round, raising nearly RMB 100 million. The investors included Jiesheng Jinrui Fund, Qianrong Chuanghe, and Yuda Venture Capital, while Xilin Investment served as the long-term exclusive financial advisor and the financial advisor for this round of transactions.The funds raised in this round will be used for the NMPA registration and certification, clinical trials, hospital market development, and brand building of its three major surgical robot products. This financing marks another milestone for Simpletouch, coming one year after its Pre-A round in July 2020.

Simpletouch Technology was established in March 2019, founded by an elite team from the medical imaging equipment and device engineering industries. Within just three years, several of its products have made rapid progress. The tumor puncture surgical robot has entered the clinical trial phase, with its product performance and experimental data receiving endorsement and recognition from numerous hospitals and experts. Simpletouch Technology has not only improved the precision of puncture biopsy by an order of magnitude but also significantly enhanced the detection rate of various complex and early-stage small tumors, thereby providing more therapeutic options for subsequent treatments such as ablation. Meanwhile, leveraging its robotic platform R&D system, the company has developed a series of products including vascular intervention robots and laparoscopic robots. As continuous product iteration and R&D efforts proceed, related products have successively entered preclinical animal trial stages.

Dr. Liu Jian, Founder of Simpletouch, stated:“An increasing array of differentiated surgical robots, characterized by personalization, precision, safety, and minimal invasiveness, continues to emerge. These diverse robotic systems are gradually being trialed and accepted across various clinical applications and therapeutic approaches. This represents a long-term process requiring continuous collaboration between medical specialists from different departments and patients, involving iterative improvements and eventual widespread adoption. Simpletouch focuses on the research and development of robotic systems for the precise early treatment of tumors, the precise treatment of cardiovascular diseases, and minimally invasive general surgery, along with corresponding innovative clinical therapeutic methods. Leveraging its years of accumulated expertise in medical industrialization, sustained technological innovation, and deep understanding of clinical needs, Simpletouch aims to continuously provide safer and more precise surgical robot platforms tailored to the distinct characteristics of different diseases, thereby consistently benefiting clinical patients and enhancing the therapeutic standards of medical experts.”

Jiesheng Jinrui Fund stated:“Robot-assisted surgery (RAS) has brought revolutionary changes to the development of surgical procedures. Compared with traditional open surgery and minimally invasive surgery, RAS significantly improves surgical precision and efficiency, enhances patient outcomes, and reduces radiation exposure time for surgeons, demonstrating substantial clinical value and broad prospects for future development. Simpletouch has established unique advantages in fields related to surgical robots, including structural design, motion control, image algorithms, and artificial intelligence. As the lead investor in this round of financing for Simpletouch, we are honored to join forces with the Simpletouch team and both new and existing investors to contribute to the development of surgical robots in China and the widespread adoption of their clinical applications.”

Ms. Ye Xiaoming, Chairwoman of Qianrong Chuanghe, stated:“Medical robots are one of the key development areas under the Made in China 2025 initiative. Simpletouch is committed to developing a range of surgical robots that can significantly address currently unmet clinical needs. Its platform-based technology, built on a differentiated approach, demonstrates unique advantages in product performance and is poised to achieve breakthroughs across multiple indications and diagnostic and therapeutic modalities. The Simpletouch team boasts strong industrialization expertise and execution capabilities, catering to the needs of both tertiary hospitals and primary care institutions to drive market penetration into lower-tier markets. Under the leadership of Dr. Liu Jian, we believe Simpletouch will carve out a distinctive and promising niche in the domestic surgical robot sector.”

Mr. Yan Xiaolong, Project Leader of the Healthcare Division at Xilin Investment and the exclusive financial advisor for this transaction, stated:“Simpletouch is one of the few exceptional teams with the systematic capability to implement large-scale medical devices. The team possesses substantial resource reserves in product commercialization, medical equipment supply chain networks, and market channels, laying a solid foundation for better serving patients with future products.”

Mr. Wen Tianli, Founder and Chairman of Xilin Investment, stated“The development of surgical robots is still in its very early stages. Global leaders such as Intuitive Surgical and Stryker Robotics are essentially still at the stage of teleoperated robotic arms. With the integration of 5G, big data, and AI with imaging equipment and device engineering, fully intelligent surgical robots reminiscent of science fiction films will undoubtedly emerge first in China. Xilin Investment is honored to have partnered twice with Dr. Liu Jian’s team, securing a strong start in the marathon of the company’s growth.”

Jiesheng Jinrui Fund was established in December 2019, jointly initiated by Xuzhou Guosheng Group, Shengshi Guojin, and government guidance funds at the provincial, municipal, and district levels. The fund adopts a dual-GP structure and is co-managed by Guosheng Furui Company and Shengshi Guojin. It focuses on high-quality market-oriented projects in emerging industries such as healthcare and life sciences, next-generation information technology, and new consumption.

Qianrong Chuanghe is the fund management company under Qianrong Group, responsible for the group’s investments in external growth-stage and mature-stage projects. Jiangsu Qianrong Group is a comprehensive investment holding group that covers the full investment cycle and entire industry chain, including angel investing, venture capital (VC), private equity (PE), mergers and acquisitions (M&A), industrial fund-of-funds, secondary market investments, and quantitative hedge strategies. The group has cumulatively invested in more than 40 technology companies and four financial institutions, among which 12 have been listed on the Shanghai and Shenzhen Stock Exchanges and the Hong Kong Stock Exchange. Notable success stories include Titan Wind Energy, Victory Precision, Neway Valve, Hengjiu Optoelectronics, Medisino, InnoLight Technology, Kangzhong Medical, and Xinhan Advanced Materials.

Xilin Investment, an elite boutique investment bank under Blue Lotus Capital Advisors, focuses on sectors such as healthcare and technology. Since its establishment in December 2014, it has facilitated over RMB 4 billion in financing for more than 30 projects. Xilin Investment maintains offices in Shenzhen, Shanghai, and Beijing.